IMVT - CIK 0001764013
Immunovant, Inc. (IMVT) reported net income of -$505.61M for fiscal year 2026, as filed in its audited annual report with the SEC.
| Fiscal year | Net Income | Change |
|---|---|---|
| FY 2026 | -$505.61M | -22.2% |
| FY 2025 | -$413.84M | -59.6% |
| FY 2024 | -$259.34M | -22.9% |
| FY 2023 | -$210.96M | -34.6% |
| FY 2022 | -$156.73M | -45.9% |
| FY 2021 | -$107.43M | -61.8% |
| FY 2020 | -$66.39M | -132.1% |
| FY 2019 | -$28.60M | - |
Immunovant, Inc. (IMVT) reported net income of -$505.61M for fiscal year 2026, as filed in its audited annual report with the SEC.
Between fiscal 2019 and fiscal 2026, Immunovant, Inc.'s net income declined from -$28.60M to -$505.61M.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.